Anecortave Acetate for Treatment of Steroid Induced Intraocular Pressure (IOP) Elevation

Alcon Research70 enrolled

Overview

The purpose of this study is to evaluate the safety and efficacy of anecortave acetate depot when administered for the treatment of elevated IOP following treatment with steroids.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Eye Diseases

Interventions

Anecortave Acetate Sterile Suspension, 6 mg/mLDRUG

One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye

Anecortave Acetate Suspension Depot, 30 mg/mLDRUG

One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye

Anecortave Acetate Sterile Suspension, 60 mg/mLDRUG

One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Either gender * 18 years of age or older * IOP elevation caused by steroid usage * Other protocol-defined inclusion criteria may apply Exclusion Criteria: * Under 18 years of age * Other protocol-defined exclusion criteria may apply

Locations (12)

Jacksonville

Jacksonville, Florida, United States

Miami

Miami, Florida, United States

Detroit

Detroit, Michigan, United States

Unnamed facility

Fort Worth, Texas, United States

Outcomes

Primary Outcomes

Mean change in IOP at Week 4 from Baseline

Time frame: Week 4

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.